Tag
A standing ovation greeted the full results of Daraxonrasib, a targeted therapy for pancreatic cancer, marking a major breakthrough. The researcher expresses inspiration that nothing is undruggable anymore.
Daraxonrasib received a standing ovation at ASCO as Revolution Medicines' breakthrough against pancreatic cancer, celebrated by over 40,000 oncologists, entrepreneurs, investors, and patient advocates.
A clinical trial found that the daily pill daraxonrasib doubles survival time for patients with pancreatic cancer, offering a significant breakthrough in treatment with fewer side effects compared to chemotherapy.